Neuphoria Therapeutics Inc. (NEUP) NASDAQ

8.44

-0.125(-1.46%)

Updated at July 30 11:40AM

Currency In USD

Neuphoria Therapeutics Inc.

Address

100 Summit Dr

Burlington,

United States of America

Phone

N/A

Sector

Healthcare

Industry

Medical - Pharmaceuticals

Employees

8

First IPO Date

December 16, 2021

Key Executives

NameTitlePayYear Born
Dr. Spyridon Papapetropoulos M.D., Ph.D.Chief Executive Officer, President & Director768,2631973
Mr. Adrian Hinton BEC, F.C.A.Financial Controller191,8931952
Ms. Elizabeth DoolinSenior Vice President of Clinical Development198,4411965
Mr. Rajeev Chandra B.Com., C.A., M.B.A.Company Secretary0N/A
Dr. Mark A. Smith M.D., Ph.D.Chief Medical Officer01955
Dr. Julie Kerner Ph.D.Senior Vice President of Business Operations0N/A

Description

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.